Pink Sheet Podcast: Wegovy’s CV Benefits, Mifepristone And Water Contamination, US FDA Back To The Office?
Pink Sheet reporters and editors discuss the impact of a study showing cardiovascular benefits for the weight loss drug Wegovy, another attempt to restrict mifepristone access, and a new threat to the US FDA’s hybrid work policy.
You may also be interested in...
The 16-year-old WWFH is closely aligned with PhRMA and focuses on ‘bringing together national and local business leaders, labor, biopharma, patient advocacy and other healthcare-related stakeholders.’
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.
Pink Sheet Podcast: FTC Ends Amgen-Horizon Case, New Ultra-Rare Cancer Partnership, Generic Applications Lag
Pink Sheet reporter and editors discuss the US Federal Trade Commission ending its attempt to block the Amgen acquisition of Horizon Therapeutics, a proposed public-private partnership to develop ultra-rare cancer drugs, and a slow-down in ANDA submissions to the US Food and Drug Administration.